SG Americas Securities LLC Buys New Position in Celcuity Inc. (NASDAQ:CELC)

SG Americas Securities LLC bought a new stake in shares of Celcuity Inc. (NASDAQ:CELCFree Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,995 shares of the company’s stock, valued at approximately $119,000.

Other large investors also recently added to or reduced their stakes in the company. Quest Partners LLC grew its position in Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after buying an additional 1,379 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Celcuity by 78.5% in the first quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock worth $193,000 after purchasing an additional 3,930 shares during the period. Commonwealth Equity Services LLC boosted its position in shares of Celcuity by 9.9% in the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after purchasing an additional 1,500 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in shares of Celcuity by 7.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock worth $361,000 after purchasing an additional 1,600 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Celcuity by 27.7% in the second quarter. Rhumbline Advisers now owns 32,464 shares of the company’s stock worth $532,000 after purchasing an additional 7,049 shares during the period. 63.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Celcuity in a research report on Thursday, August 15th. Stifel Nicolaus boosted their target price on shares of Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Lifesci Capital started coverage on shares of Celcuity in a report on Monday, August 26th. They issued an “outperform” rating and a $27.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Celcuity in a report on Thursday, August 15th. Finally, Leerink Partnrs raised shares of Celcuity to a “strong-buy” rating in a report on Monday, July 22nd. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $29.17.

View Our Latest Research Report on CELC

Celcuity Trading Down 1.2 %

Shares of CELC opened at $15.61 on Friday. Celcuity Inc. has a twelve month low of $9.36 and a twelve month high of $22.19. The company has a market cap of $547.93 million, a P/E ratio of -5.62 and a beta of 0.75. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54. The company’s fifty day simple moving average is $15.51 and its 200-day simple moving average is $16.25.

Celcuity (NASDAQ:CELCGet Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. During the same quarter in the previous year, the company posted ($0.66) earnings per share. As a group, analysts expect that Celcuity Inc. will post -2.54 EPS for the current year.

About Celcuity

(Free Report)

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Featured Stories

Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity Inc. (NASDAQ:CELCFree Report).

Institutional Ownership by Quarter for Celcuity (NASDAQ:CELC)

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.